KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables: 2011-2024

Historic Payables for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $76.4 million.

  • Supernus Pharmaceuticals' Payables rose 43.28% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.6 million, marking a year-over-year increase of 4.69%. This contributed to the annual value of $76.4 million for FY2024, which is 4.04% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Payables of $76.4 million as of FY2024, which was down 4.04% from $79.6 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Payables peaked at $498.3 million during FY2022, and registered a low of $76.4 million during FY2024.
  • Moreover, its 3-year median value for Payables was $79.6 million (2023), whereas its average is $218.1 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Payables skyrocketed by 323.43% in 2022, and later crashed by 84.03% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Payables stood at $78.9 million in 2020, then surged by 49.09% to $117.7 million in 2021, then spiked by 323.43% to $498.3 million in 2022, then plummeted by 84.03% to $79.6 million in 2023, then declined by 4.04% to $76.4 million in 2024.